Sunshine Biopharma (NASDAQ: SBFM) pays CAD$1.5M to settle Nora Pharma dispute
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Sunshine Biopharma Inc., through its wholly owned subsidiary Nora Pharma Inc., entered into an agreement of transaction and mutual release with Nora’s former president, Malek Chamoun, on July 8, 2026. Under this agreement, Sunshine Biopharma agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties. The agreement functions as a comprehensive release, aiming to conclude outstanding claims between the company, Nora, and Mr. Chamoun.
Positive
- None.
Negative
- None.
Insights
Settlement resolves an internal dispute with a defined cash cost.
The company committed to pay CAD$1,500,000 (about US$1,058,565) to Nora Pharma’s former president, Malek Chamoun, under a transaction and mutual release agreement. This brings a specific dispute to a contractual conclusion and should reduce management distraction around this issue.
The cash payment represents an outflow from Sunshine Biopharma, but the filing does not quantify its scale relative to revenue or cash on hand. The agreement is dated July 8, 2026, with the form signed on July 10, 2026, providing a clear timeline for when the settlement obligations were established.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Settlement amount: CAD$1,500,000
Approximate US dollar equivalent: US$1,058,565
Agreement date: July 8, 2026
+2 more
5 metrics
Settlement amount
CAD$1,500,000
Cash payment agreed to be paid to former Nora Pharma president in full and final settlement of a dispute
Approximate US dollar equivalent
US$1,058,565
Approximate U.S. dollar value of the CAD$1,500,000 settlement payment
Agreement date
July 8, 2026
Date Sunshine Biopharma and Nora Pharma entered into the Release Agreement with Malek Chamoun
Filing signature date
July 10, 2026
Date the report was signed by the Chief Executive Officer of Sunshine Biopharma
Exhibit number for Release Agreement
10.1
Exhibit in which the full text of the Release Agreement is filed
Key Terms
material definitive agreement, mutual release, wholly-owned subsidiary, full and final settlement, +1 more
5 terms
material definitive agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
mutual release legal
"entered into an agreement of transaction and mutual release"
wholly-owned subsidiary financial
"the Company’s wholly-owned subsidiary, Nora Pharma Inc."
A wholly-owned subsidiary is a company whose entire ownership is held by another company, called the parent, so the parent controls all shares, board appointments and major decisions. For investors this matters because the subsidiary’s profits, losses, assets and liabilities are treated as part of the parent’s financial picture, affecting valuation and risk exposure — imagine a parent owning a single storefront outright and consolidating its receipts and bills into the parent’s books.
full and final settlement legal
"in full and final settlement of a dispute between the parties"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What agreement did Sunshine Biopharma (SBFM) enter into on July 8, 2026?
Sunshine Biopharma entered into an agreement of transaction and mutual release with Nora Pharma Inc. and former Nora president Malek Chamoun, resolving a dispute between the parties through a defined settlement payment.
How much is Sunshine Biopharma (SBFM) paying in the settlement with Malek Chamoun?
Sunshine Biopharma agreed to pay CAD$1,500,000, described as approximately US$1,058,565, to former Nora Pharma president Malek Chamoun as full and final settlement of a dispute between them.
Who are the parties to Sunshine Biopharma’s (SBFM) Release Agreement?
The Release Agreement is among Sunshine Biopharma Inc., its wholly owned subsidiary Nora Pharma Inc., and Malek Chamoun, who previously served as president of Nora Pharma, settling a dispute between these parties.
What is the purpose of the settlement disclosed by Sunshine Biopharma (SBFM)?
The payment of CAD$1,500,000 to Malek Chamoun is described as being in full and final settlement of a dispute between Sunshine Biopharma, its subsidiary Nora Pharma, and Mr. Chamoun, and is tied to a mutual release agreement.
Where can investors find the full terms of Sunshine Biopharma’s (SBFM) Release Agreement?
The company states that the summary is qualified by the full Release Agreement, which is filed as Exhibit 10.1, allowing investors to review the complete contractual terms in that exhibit.